Riik: Malta
keel: inglise
Allikas: Medicines Authority
ondansetron 8 mg
Glaxo Wellcome UK Limited
A04AA01
ondansetron
film-coated tablet
Authorised
2006-09-18
MHRA Submission: Type II variation GDS 37 consistency updates and QRD template update less ADR Toxic skin eruptions Text Version: 1/8/2013 MHRA Approval Date: 04/09/2014 Text Version: Issue 8 Draft 2 SmPC Version: Issue10 Draft 2 - 1 - GLAXOSMITHKLINE (LOGO) PACKAGE LEAFLET: INFORMATION FOR THE USER ZOFRAN® TABLETS 4 MG AND 8 MG ONDANSETRON (AS HYDROCHLORIDE DIHYDRATE) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions about your illness or your medicine, ask your doctor, nurse or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist (see section 4). WHAT IS IN THIS LEAFLET: 1 What Zofran tablets are and what they are used for 2 What you need to know before you take Zofran tablets 3 How to take Zofran tablets 4 Possible side effects 5 How to store Zofran tablets 6 Contents of the pack and other information 1 WHAT ZOFRAN TABLETS ARE AND WHAT THEY ARE USED FOR Zofran tablets contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics. Zofran tablets are used for: preventing nausea and vomiting caused by chemotherapy [http://www.netdoctor.co.uk/medicines/effect/cancer.shtml](in adults and children) or radiotherapy for cancer [http://www.netdoctor.co.uk/cancer/index.shtml](adults only) preventing nausea and vomiting after surgery (adults only). Ask Lugege kogu dokumenti
SUMMARY OF PRODUCT CHARACTERISTICS PRODUCT SUMMARY 1. TRADE NAME OF THE MEDICINAL PRODUCT Zofran Tablets 8mg. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Zofran Tablet 8mg is a yellow, oval, film coated tablet engraved "GXET5" on one face and plain on the other. Each tablet contains ondansetron 8mg (as hydrochloride dihydrate). 3. PHARMACEUTICAL FORM Film coated tablet. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _ADULTS: _ Zofran tablets are indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran tablets are indicated for the prevention of post-operative nausea and vomiting (PONV). For treatment of established PONV, administration by injection is recommended. _PAEDIATRIC POPULATION: _ Zofran is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months. F or the prevention and treatment of PONV in children aged ≥1 month administration by injection is recommended. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING ADULTS: The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection Page 1 of 16 of dose regimen should be determined by the severity of the emetogenic challenge. _Emetogenic Chemotherapy and Radiotherapy:_ Zofran can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration. For oral administration: 8mg taken1 to 2 hours before chemotherapy or radiation treatment, followed by 8mg every 12 hours for a maximum of 5 days to protect against delayed or prolonged emesis. _For highly emetogenic chemotherapy: _a si Lugege kogu dokumenti